Relmada Therapeutics, Inc. (RLMD) News
Filter RLMD News Items
RLMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RLMD News Highlights
- RLMD's 30 day story count now stands at 4.
- Over the past 13 days, the trend for RLMD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- MG, CNS and DRUG are the most mentioned tickers in articles about RLMD.
Latest RLMD News From Around the Web
Below are the latest news stories about Relmada Therapeutics Inc that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada posts topline data for lead asset in abuse potential trial against ketamineThe development stage biotech company, Relmada Therapeutics (NASDAQ:RLMD) announced on Wednesday the topline results from the human abuse potential (HAP) study for its lead candidate REL-1017, currently in Phase 3 development for major depressive disorder (MDD). The Phase 1 study was designed to assess the abuse potential of REL-1017 vs.... |
Relmada Aces REL-1017 Vs Ketamine Study For Abuse PotentialRelmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate. The results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational drug users demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes |
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse PotentialRelmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD). |
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceRelmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time. |
Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Analysts’ Top Healthcare Picks: LHC Group (LHCG), BridgeBio Pharma (BBIO)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LHC Group (LHCG – Research Report), BridgeBio Pharma (BBIO – Research Report) and Relmada Therapeutics (RLMD – Research Report) with bullish sentiments. LHC Group (LHCG) Jefferies analyst Brian Tanquilut maintained a Buy rating on LHC Group on December 27 and set a price target of $200.00. The company's shares closed last Tuesday at $137.90. According to TipRanks. |
Data - Relmada Therapeutics Price Target Lowered to $42.00 at SVB LeerinkRelmada Therapeutics had its price objective decreased by SVB Leerink from $50.00 to $42.00 in a research report sent to investors on Monday morning, PriceTargets.com reports… |
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of PsychiatryRelmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of Phase 2 data from the clinical study of REL-1017 as adjunctive treatment for patients with major depressive disorder (MDD) in the peer-reviewed American Journal of Psychiatry, the most widely read psychiatric journal in the world. The article is titled, "REL-1017 (Esmethadone) as Adjunctive Treatment in Patients with Major Depre |
Brokerages Expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) to Post -$1.87 EPSEquities analysts forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD) will post earnings per share (EPS) of ($1.87) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Relmada Therapeutics earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.79). Relmada Therapeutics reported earnings per share of ($1.28) in the [] |
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $172.5 Million Upsized Public Offering Underwritten by Goldman Sachs and JefferiesNEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, in an upsized underwritten public offering. The offering, including the full exercise of the overallotment, consisted of 10,147,059 shares of common stock at a price to the public of $17.00 per share. The gross proceeds of the offering to the company were approxim |